| | |

Tag search: "Roche"

Non communicable diseases

Scientists find new biomarker to guide cancer immunotherapy

Scientists said they have pinpointed a particular type of immune system cell that could predict more precisely if cancer patients are likely to respond to modern immunotherapy medicines. The discovery, reported in the journal Nature Immunology, suggests doctors and drug developers will need to get smarter in zeroing in on those people who stand to benefit from the expensive new drugs, which are revolutionizing cancer care. Drugs such as Merck & Co`s Keytruda, Bristol-Myers Squibb`s Opdivo, Roche`s Tecentriq and AstraZeneca`s Imfinzi can boost the immune system`s ability to fight tumors, but they only work for some patients

June 13, 2017
Reuters

Roche's star cancer drug stumbles in study, raising doubts about future

Roche’s Tecentriq immune-oncology drug failed a late-stage follow-up trial against advanced bladder cancer, the Swiss drug maker said, raising questions about whether regulators could scale back their approval of the medicine. U.S. fast-track approval for Tecentriq against bladder cancer had been agreed but subject to success at these further trials

May 10, 2017
Reuters

U.S. approves Roche drug that targets severe form of MS

Roche’s multiple sclerosis drug Ocrevus won U.S. approval, putting it back on track after a brief delay and giving a lift to patients with a more severe form of the disease that until now had no approved treatment

March 29, 2017
Reuters

Roche trial finds new drug cocktail cuts breast cancer deaths

Roche’s bid to shield its ageing but lucrative oncology franchise from cheaper copies got a lift from a trial showing a new drug cocktail kept breast cancer patients alive longer. Combining its drug Perjeta with Herceptin and chemotherapy after surgery, cut recurrence of an aggressive type of early breast cancer or death, when compared to just Herceptin and chemo

March 2, 2017
Reuters

Health systems

UK will pay for Roche breast cancer drug at centre of price row

A Roche breast cancer drug at the centre of a prolonged pricing row in Britain will now be paid for routinely, following a discount deal between the company and the National Health Service. Kadcyla, which can prolong the lives of some women with advanced disease, has been a battle-ground for campaigners wanting better access to modern cancer drugs, with 115,000 people signing a petition demanding its availability. The National Institute for Health and Care Excellence said it could now recommend funding for Kadcyla, following the commercial access arrangement with Roche

June 15, 2017
Reuters

Pfizer, Roche and Aspen face South African probe into cancer drug prices

South Africa`s competition watchdog has launched an investigation into three drug companies accused of over-charging for cancer medicines, the agency`s chief said. Tembinkosi Bonakele, head of the Competition Commission, said the agency would investigate Aspen Pharmacare, Africa`s biggest generic drug maker, U.S. company Pfizer and Swiss-based Roche Holding. The Commission, which investigates cases before bringing them to the Competition Tribunal for adjudication, said it suspected the lung cancer treatment xalkori crizotinib sold by Pfizer had been excessively priced as have the breast cancer drugs Herceptin and Herclon sold by Roche. It also said it would look into whether Aspen, a local company based in Durban, might have over-charged for Leukeran, Alkeran and Myleran cancer treatments in South Africa

June 13, 2017
Reuters

Roche vs Indian Pharma: The battle for a cheaper cancer drug

On April 25, the Competition Commission of India released an order opening an investigation against Roche for blocking the entry of biosimilar versions of Trastuzumab, globally sold under the brand name Herceptin. The CCI’s 36-page order notes that prima facie it appears that Roche used its dominant position to influence regulators and medical professionals against prescribing the biosimilar versions of Trastuzumab manufactured by several Indian drug makers, including Biocon and Mylan. The two companies complained that Roche’s anti-competitive measures ranged from suing the Indian regulator for granting approval to manufacture biosimilars to selectively using the court’s observations to ‘intimidate’ doctors, chemists and state hospitals 

May 14, 2017
Economic Times

India's antitrust watchdog orders probe into Roche cancer drug

India’s anti-trust regulator has ordered a probe into Roche for using anti-competitive practices to restrict cheaper copies of a blockbuster drug from reaching patients. Roche’s Trastuzumab is being challenged by several biosimilars which are sold at about 25% discount to the original. India’s Biocon and U.S. firm Mylan, which sell biosimilars of the drug in over a dozen countries including India, filed a complaint with the Competition Commissioner of India alleging Roche misled doctors and regulators to thwart competition to trastuzumab

April 26, 2017
Reuters

The cost of cancer: new drugs show success at a steep price

Newer cancer drugs that enlist the body’s immune system are improving the odds of survival, but competition between them is not reigning in prices that can now top $250,000 per year

April 3, 2017
Reuters